Anthranilamide-Pyrazolo[1,5-a]pyrimidine Conjugates as p53 Activators in Cervical Cancer Cells

ChemMedChem

Volumn 7, Issue 8, 2012, Pages 1453-1464

  Kamal, Ahmed ^a   Tamboli, Jaki R ^a   Ramaiah, M Janaki ^a   Adil, S F ^b   KoteswaraRao, G ^a   Viswanath, A ^a   Mallareddy, Adla ^a   Pushpavalli, S N C V L ^a   Pal Bhadra, Manika ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antitumor agents; Apoptosis; Caspase 3; Cell cycle; Roscovitine

Indexed keywords

4 [2 (FURAN 2 YLMETHYLAMINO) BENZOYL] PIPERAZIN 1 YL] [7 (4 NITROPHENYL) 2 PHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL) METHANONE; [2 PHENYL 7 (3,4,5 TRIMETHOXYPHENYL) PYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (3,4,5 TRIMETHOXYBENZYLAMINO) BENZOYL] PIPERAZIN 1 YL] METHANONE; [2 PHENYL 7 (3,4,5 TRIMETHOXYPHENYL) PYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (THIOPHEN 2 YLMETHYLAMINO) BENZOYL] PIPERAZIN 1 YL) METHANONE; [2 PHENYL 7 PARA TOLYLPYRAZOLO (1,5 ALPA) PYRIMIDIN 5 YL] [4 [2 (3,4,5 TRIMETHOXYBENZYLAMINO) BENZOYL] PIPERAZIN 1 YL] METHANONE; [2 PHENYL 7 PARA TOLYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (THIOPHEN 2 YLMETHYLAMINO) BENZOYL] PIPERAZIN 1 YL] METHANONE; [2,7 DIPHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (3,4,5 TRIMETHOXYBENZYLAMINO) BENZOYL] PIPERAZIN 1 YL] METHANONE; [2,7 DIPHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (FURAN 2 YLMETHYLAMINO) BENZOYL] IPERAZINE 1 YL] METHANONE; [2,7 DIPHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (THIOPHEN 2 YLMETHYLAMINO) BENZOYL] IPERAZINE 1 YL] METHANONE; [4 [2 (FURAN 2 YLMETHYLAMINO) BENZOYL] PIPERAZIN 1 YL] [2 PHENYL 7 PARA TOLYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] METHANONE; [4 [2 [BENZO (DEXTRO) (1,3) DIOXOL 4 YLMETHYLAMINO] BENZOYL] PIPERAZIN 1 YL] [2,7 DIPHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] METHANONE; [4 [2 [BENZO (DEXTRO) (1,3) DIOXOL 5 YLMETHYLAMINO] BENZOYL] PIPERAZIN 1 YL] [2 PHENYL 7 (3,4,5 TRIMETHOXYPHENYL) PYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] METHANONE; [4 [2 [BENZO (DEXTRO) (1,3) DIOXOL 5 YLMETHYLAMINO] BENZOYL] PIPERAZIN 1 YL] [2,7 DIPHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] METHANONE; [4 [2 [BENZO (DEXTRO) (1,3) DIOXOL 5 YLMETHYLAMINO] BENZOYL] PIPERAZIN 1 YL] [7 (3,4DIMETHOXYPHENYL) 2 PHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] METHANONE; [4 [2 [BENZO (DEXTRO) (1,3) DIOXOL 5 YLMETHYLAMINO] BENZOYL] PIPERAZIN 1 YL] [7 (4 METHOXYPHENYL) 2 PHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] METHANONE; [7 (3,4 DIMETHOXYPHENYL) 2 PHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (THIOPHEN 2 YLMETHYLAMINO) BENZOYL] PIPERAZIN 1 YL] METHANONE; [7 (3,4 DIMETHOXYPHENYL] 2 PHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5YL] [4 [2 (3,4,5 TRIMETHOXYBENZYLAMINO) BENZOYL] PIPERAZIN 1 YL] METHANONE; [7 (4 METHOXYPHENYL) 2 PHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (THIOPHEN 2 YLMETHYLAMINO) BENZOYL] PIPERAZIN 1 YL] METHANONE; [7 (4 NITROPHENYL) 2 PHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (3,4,5 TRIMETHOXYBENZYLAMINO) BENZOYL] PIPERAZIN 1 YL] METHANONE; [7 (4 NITROPHENYL) 2 PHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (THIOPHEN 2 YLMETHYL) BENZOYL] PIPERAZIN 1 YL) METHANONE; [7 (4METHOXYPHENYL) 2 PHENYLPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 YL] [4 [2 (3,4,5 TRIMETHOXYBENZYLAMINO) BENZOYL] PIPERAZIN 1 YL] METHANONE; ANTHRANILAMIDE PYRAZOLO (1,5 ALPHA) PYRIMIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; FLAVOPIRIDOL; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; ROSCOVITINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; KIDNEY CANCER; LEUKEMIA; LUNG NON SMALL CELL CANCER; M PHASE CELL CYCLE CHECKPOINT; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HELA CELLS; HUMANS; K562 CELLS; MCF-7 CELLS; ORTHO-AMINOBENZOATES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864410067     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201200205     Document Type: Article

References (42)

1. N. Munoz, F. X. Bosch, S. deSanjose, K. V. Shah, Mutat. Res. 1994, 305, 293-301.
2. R. Sankaranarayanan, A. M. Budukh, R. RajKumar, Bull. World Health Organ. 2001, 79, 954-962.
3. J. Wesierska-Gadek, G. Schmid, Expert Opin. Invest. Drugs 2006, 15, 23-38.
4. B. B. Zhou, J. Bartek, Nat. Rev. Cancer 2004, 4, 216-225.
5. S. S. Liu, K. Y. K. Chan, R. C. Y. Leung, H. K. W. Law, T. W. Leung, H. Y. S. Ngan, Mol. Cancer Ther. 2006, 5, 1209-1215.
6. J. Wesierska-Gadek, S. Wandl, M. P. Kramer, C. Pickem, V. Krystof, S. B. Hajek, J. Cell. Biochem. 2008, 105, 1161-1171.
7. B. Saha, A. Adhikary, P. Ray, S. Saha, S. Chakraborty, S. Mohanty, K. Das, S. Mukherjee, M. Mazumdar, L. Lahiri, D. M. S. Hossain, G. Sa, T. Das, Oncogene 2012, 31, 173-186.
8. M. Scheffner, B. A. Werness, J. M. Huibregtse, A. J. Levine, P. M. Howley, Cell 1990, 63, 1129-1136.
9. S. Schenone, O. Bruno, F. Bondavalli, A. Ranise, L. Mosti, G. Menozzi, P. Fossa, S. Donnini, A. Santoro, M. Ziche, F. Manetti, M. Botta, Eur. J. Med. Chem. 2004, 39, 939-945.
10. D. C. Kim, Y. R. Lee, B. Yang, K. J. Shin, D. J. Kim, B. Y. Chung, K. H. Yoo, Eur. J. Med. Chem. 2008, 38, 525-532.
11. S. Schenone, O. Bruno, A. Ranise, F. Bondavalli, P. Fossa, L. Mosti, G. Menozzi, F. Carraro, A. Naldini, C. Bernini, F. Manetti, M. Botta, Bioorg. Med. Chem. Lett. 2004, 14, 2511-2517.
12. R. Morisi, M. Celano, E. Tosi, S. Schenone, M. Navarra, E. Ferretti, G. Costante, C. Durante, G. Botta, M. D. Agostino, C. Brullo, S. Filetti, M. Botta, D. Russo, J. Endocrinol. Invest. 2007, 30, RC31-RC34.
13. A. Angelucci, S. Schenone, G. L. Gravina, P. Muzi, C. Festuccia, C. Vicentini, M. Botta, M. Bologna, Eur. J. Cancer 2006, 42, 2838-2845.
14. M. E. Fraley, W. F. Hoffman, R. S. Rubino, R. W. Hungate, A. J. Tebben, R. Z. R. Z. Rutledge, R. C. McFall, W. R. Huckle, R. L. Kendall, K. E. Coll, K. A. Thomas, Bioorg. Med. Chem. Lett. 2002, 12, 2767-2770.
15. M. E. Fraley, R. S. Rubino, W. F. Hoffman, S. R. Hambaugh, K. L. Arrington, R. W. Hungate, M. T. Bilodeau, A. J. Tebben, R. Z. Rutledge, R. L. Kendall, R. C. McFall, W. R. Huckle, K. E. Coll, K. A. Thomas, Bioorg. Med. Chem. Lett. 2002, 12, 3537-3541.
16. V. Krystof, D. Moravcova, M. Paprskarova, P. Barbier, V. Peyrot, A. Hlobikova, L. Havlicek, M. Stramd, Eur. J. Med. Chem. 2006, 41, 1405-1411.
17. K. C. Bible, J. L. Lensing, S. A. Nelson, Y. K. Lee, J. M. Reid, M. M. Ames, C. R. Isham, J. Piens, S. L. Rubin, J. Rubin, S. H. Kaufmann, P. J. Atherton, J. A. Sloan, M. K. Daiss, A. A. Adjei, C. Erlichman, Clin. Cancer Res. 2005, 11, 5935.
18. S. J. McClue, D. Blake, R. Clarke, A. Cowan, L. Cummings, P. M. Fischer, M. MacKenzie, J. Melville, K. Stewart, S. Wang, N. Zhelev, D. Zheleva, D. P. Lane, Int. J. Cancer 2002, 102, 463.
19. R. N. Misra, H. Xiao, K. S. Kim, S. Lu, W. C. Han, S. A. Barbosa, J. T. Hunt, D. B. Rawlins, W. Shan, S. Z. Ahmed, L. Qian, B. C. Chen, R. Zhao, M. S. Bednarz, K. A. Kellar, J. G. Mulheron, R. Batorsky, U. Roongta, A. Kamath, P. Marathe, S. A. Ranadive, J. S. Sack, J. S. Tokarski, N. P. Pavletich, F. Y. F. Lee, K. R. Webster, S. D. Kimball, J. Med. Chem. 2004, 47, 1719.
20. J. S. Sebolt-Leopold, D. T. Dudley, R. Herrera, K. VanBecelaere, A. Wiland, R. C. Gowan, H. Tecle, S. D. Barrett, A. Bridges, S. Przybranowski, W. R. Leopold, A. R. Saltiel, Nat. Med. 1999, 5, 810.
21. L. F. Allen, J. Sebolt-Leopold, M. B. Meyer, Semin. Oncol. 2003, 30, 105.
22. P. W. Manley, P. Furet, G. Bold, J. Brüggen, J. Mestan, T. Meyer, C. R. Schnell, J. Wood, J. Med. Chem. 2002, 45, 5687.
23. P. W. Manley, G. Bold, J. Brüggen, G. Fendrich, P. Furet, J. Mestan, C. R. Schnell, B. Stolz, T. Meyer, B. Meyhack, W. Stark, A. Strauss, J. Wood, Biochim. Biophys. Acta 2004, 17, 1697.
24. A. E. Shchekotikhin, A. A. Shtil, Y. N. Luzikov, T. V. Bobrysheva, V. N. Buyanov, M. N. Preobrazhenskaya, Bioorg. Med. Chem. 2005, 13, 2285.
25. A. Kamal, M. N. A. Khan, Y. V. V. Srikanth, K. S. Reddy, A. Juvekar, S. Sen, N. Kurian, S. Zingde, Bioorg. Med. Chem. 2008, 16, 7804.
26. A. Kamal, X. Rajender, D. R. Reddy, M. K. Reddy, G. Balakishan, T. BashaShaik, M. Chourasia, G. N. Sastry, Bioorg. Med. Chem. 2009, 17, 1557.
27. W. M. Cholody, L. Hernandez, L. Hassner, D. A. Scudiero, D. B. Djurickovic, C. J. Michejda, J. Med. Chem. 1995, 38, 3043.
28. Y. Najajreh, J. M. Perez, C. Navarro-Ranninger, D. Gibson, J. Med. Chem. 2002, 45, 5189.
29. C. Maurin, F. Bailly, P. Cotelle, Tetrahedron 2004, 60, 6479-6486.
30. M. J. J. Nolsoe, D. Weigelt, J. Heterocycl. Chem. 2009, 46, 1-9.
31. A. Kamal, E. V. Bharathi, M. J. Ramaiah, S. Reddy, D. Dastagiri, A. Viswanath, F. Sultana, S. N. C. V. L. Pushpavalli, M. Pal-Bhadra, A. Juvekar, S. Sen, S. Zingde, Bioorg. Med. Chem. Lett. 2010, 20, 3310-3313.
32. T. Slater, Biochim. Biophys. Acta 1963, 77, 383;
33. A. A. J. van de Loosdrecht, Immunol. Methods 1994, 174, 311;
34. M. C. Alley, Cancer Res. 1988, 48, 589.
35. J. Wesierska-Gadek, A. Borza, O. Komina, M. Maurer, Acta Biochim. Pol. 2009, 56, 495-501.
36. S. Durland-Busbice, D. Reisman, Leukemia 2002, 16, 2165-2167.
37. M. Kralj, K. Husnjak, T. Korbler, J. Pavelic, Cancer Gene Ther. 2003, 10, 457-467.
38. I. M. Ghobrial, T. E. Wittig, A. A. Adjei, Ca-Cancer J. Clin. 2005, 55, 178-194.
39. E. A. Komarova, M. V. Chernov, R. Franks, K. Wang, G. Armin, C. R. Zelnick, D. M. Chin, S. S. Bacus, G. R. Stark, A. V. Gudkov, EMBO J. 1997, 16, 1391-1400.
40. R. Kaul, S. Mukherjee, F. Ahmed, M. J. Bhat, R. Chhipa, S. Galande, S. Chattopadhyay, Int. J. Cancer 2003, 103, 606-615.
41. X. Wang, X. Jiang, Annu. Rev. Biochem. 2004, 73, 87-106.
42. A. G. Porter, R. U. Janicke, Cell Death Differ. 1999, 6, 99-104.